Peer-reviewed veterinary case report
Artificial lymphatic system boosts carboplatin blood flow in dog bone
By DiResta, Gene R et al.·Published in Annals of surgical oncology·2007·Orthopaedic Surgical Service, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Use of an artificial lymphatic system during carboplatin infusion to improve canine osteosarcoma blood flow and clinical response.
- Species:
- dog
Plain-English summary
A group of dogs with osteosarcoma, a type of bone cancer, received chemotherapy with carboplatin while using a special device called an artificial lymphatic system (ALS) to improve blood flow to the tumors. The ALS helped increase blood flow significantly and allowed more of the chemotherapy drug to reach the tumors. However, even with these improvements, the overall survival rates for dogs treated with the ALS were similar to those without it. This suggests that while the ALS may help deliver chemotherapy better, it did not change the long-term outcomes for these dogs.
People also search for: dog osteosarcoma treatment · carboplatin for dogs · artificial lymphatic system in dogs
Abstract
BACKGROUND: The artificial lymphatic system (ALS), a mechanical system designed to reduce increased interstitial fluid pressure in solid tumors and enhance the delivery of chemotherapy, was evaluated within a randomized clinical trial treating spontaneously occurring canine appendicular osteosarcoma (OS), a tumor similar to its human OS counterpart. METHODS: An ALS was investigated for its ability to increase OS blood flow and increase uptake of intravenously administered carboplatin. RESULTS: Blood flow increased by 314% in tumors with active ALS drains versus 126% in control tumors (P < .03). Tumor carboplatin uptake increased by 51% after drain activation (P = .07). Microvascular density (MVD) was measured in tumors after surgical amputation and in corresponding bone regions in a cohort of normal dogs. The OS tumors had equivalent MVD as normal bone, and MVD was higher in the humerus than the femur (P < .03) in both tumor and normal bone. Median survival between the ALS-treated and control cohorts was not different despite increased drug uptake or ALS manipulation. Compared with historic controls, ALS drain insertion into tumors to reduce interstitial fluid pressure did not worsen the prognosis. CONCLUSIONS: The findings in canine spontaneously occurring OS indicate that an ALS may be of value as a chemotherapy adjunct for enhancing the delivery of chemotherapy to tumor interstitium.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17503157/